TMS Co., Ltd. Reports Positive Phase I Results for TMS-008

TMS Co., Ltd. ( (JP:4891) ) has provided an announcement.

TMS Co., Ltd. announced the first data readout from its Phase I clinical trial of TMS-008, which showed good safety and tolerability in healthy adult male subjects. TMS-008, part of the SMTP compound family, has strong anti-inflammatory and antioxidant properties and is being developed as a potential treatment for acute kidney injury. While the trial results will not impact the company’s current financial year, they are expected to enhance mid-to-long-term business performance.

More about TMS Co., Ltd.

TMS Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to discovering and developing transformative medicines for serious diseases with high unmet medical needs. The company focuses on a pipeline of small molecule compounds known as SMTPs, derived from a fungus, and has programs targeting conditions such as acute ischemic stroke, resistant hypertension, acute kidney injury, and spinal cord injury.

YTD Price Performance: -34.86%

Average Trading Volume: 1,863,122

Technical Sentiment Signal: Strong Buy

Current Market Cap: Yen5.73B

For a thorough assessment of 4891 stock, go to TipRanks’ Stock Analysis page.